Eli Lilly And Stock Year To Date Return

LLY Stock

USD 813.48 11.83 1.48%

Eli Lilly and fundamentals help investors to digest information that contributes to Eli Lilly's financial success or failures. It also enables traders to predict the movement of Eli Stock. The fundamental analysis module provides a way to measure Eli Lilly's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Eli Lilly stock.

Short Long Term Debt Total Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Eli Lilly and Company Year To Date Return Analysis

Eli Lilly's Year to Date Return (YTD) is the total return generated from holding a security from the beginning of the current fiscal year. In other words, YTD Return represents the capital appreciation of your investments from the start of the current fiscal year.

YTD Return

(Mean of Monthly Returns - 1)

X

100%

More About Year To Date Return | All Equity Analysis

Eli Year To Date Return Driver Correlations

Understanding the fundamental principles of building solid financial models for Eli Lilly is extremely important. It helps to project a fair market value of Eli Stock properly, considering its historical fundamentals such as Year To Date Return. Since Eli Lilly's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Eli Lilly's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Eli Lilly's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Net Receivables	Total Liab	Total Current Assets	Intangible Assets	Short Term Debt	Accounts Payable	Short Term Investments	Capital Stock	Common Stock	Long Term Debt	Treasury Stock	Property Plant Equipment	Good Will	Current Deferred Revenue	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Long Term Investments	Short Long Term Debt	Cash And Equivalents	Net Invested Capital	Net Working Capital
Total Assets		0.16	0.06	0.08	0.95	0.97	0.02	0.65	0.84	0.98	-0.33	-0.73	-0.73	0.92	0.54	0.82	0.65	0.86	-0.47	0.63	0.78	-0.14	0.79	-0.44	0.66	-0.35
Total Stockholder Equity	0.16		-0.32	0.97	-0.01	-0.07	0.08	-0.14	0.11	0.11	0.69	0.47	0.47	-0.17	-0.07	0.35	0.01	-0.01	0.67	-0.44	-0.23	0.7	-0.01	0.17	0.31	0.16
Net Debt	0.06	-0.32		-0.32	0.29	0.17	0.78	0.57	-0.08	0.05	-0.32	-0.36	-0.36	0.06	0.37	0.28	0.44	0.2	-0.54	0.51	0.36	-0.24	0.19	-0.36	-0.19	-0.63
Retained Earnings	0.08	0.97	-0.32		-0.12	-0.14	0.13	-0.18	0.01	0.01	0.77	0.57	0.57	-0.26	-0.02	0.28	-0.03	-0.15	0.68	-0.5	-0.31	0.78	-0.11	0.31	0.15	0.28
Net Receivables	0.95	-0.01	0.29	-0.12		0.97	0.14	0.75	0.79	0.95	-0.51	-0.84	-0.84	0.92	0.51	0.81	0.69	0.91	-0.6	0.76	0.85	-0.29	0.81	-0.58	0.64	-0.53
Total Liab	0.97	-0.07	0.17	-0.14	0.97		0.03	0.71	0.81	0.96	-0.5	-0.85	-0.85	0.97	0.57	0.78	0.69	0.87	-0.65	0.77	0.87	-0.3	0.8	-0.51	0.6	-0.4
Total Current Assets	0.02	0.08	0.78	0.13	0.14	0.03		0.25	-0.2	-0.1	0.05	0.03	0.03	-0.16	0.29	0.35	0.21	-0.11	-0.19	0.23	0.16	0.13	0.06	0.15	-0.28	-0.2
Intangible Assets	0.65	-0.14	0.57	-0.18	0.75	0.71	0.25		0.36	0.67	-0.4	-0.74	-0.74	0.67	0.53	0.64	0.78	0.75	-0.72	0.75	0.71	-0.17	0.43	-0.71	0.25	-0.64
Short Term Debt	0.84	0.11	-0.08	0.01	0.79	0.81	-0.2	0.36		0.87	-0.26	-0.57	-0.57	0.79	0.29	0.56	0.52	0.79	-0.25	0.39	0.55	-0.12	0.92	-0.41	0.78	-0.42
Accounts Payable	0.98	0.11	0.05	0.01	0.95	0.96	-0.1	0.67	0.87		-0.38	-0.76	-0.76	0.94	0.48	0.76	0.67	0.92	-0.47	0.62	0.76	-0.19	0.82	-0.57	0.72	-0.45
Short Term Investments	-0.33	0.69	-0.32	0.77	-0.51	-0.5	0.05	-0.4	-0.26	-0.38		0.78	0.78	-0.59	-0.26	-0.2	-0.27	-0.42	0.75	-0.75	-0.68	0.88	-0.29	0.46	-0.2	0.27
Capital Stock	-0.73	0.47	-0.36	0.57	-0.84	-0.85	0.03	-0.74	-0.57	-0.76	0.78		1.0	-0.88	-0.49	-0.5	-0.58	-0.81	0.85	-0.86	-0.85	0.66	-0.61	0.64	-0.36	0.52
Common Stock	-0.73	0.47	-0.36	0.57	-0.84	-0.85	0.03	-0.74	-0.57	-0.76	0.78	1.0		-0.88	-0.49	-0.5	-0.58	-0.81	0.85	-0.86	-0.85	0.66	-0.61	0.64	-0.36	0.52
Long Term Debt	0.92	-0.17	0.06	-0.26	0.92	0.97	-0.16	0.67	0.79	0.94	-0.59	-0.88	-0.88		0.52	0.68	0.65	0.87	-0.68	0.78	0.86	-0.41	0.75	-0.54	0.62	-0.35
Treasury Stock	0.54	-0.07	0.37	-0.02	0.51	0.57	0.29	0.53	0.29	0.48	-0.26	-0.49	-0.49	0.52		0.56	0.62	0.42	-0.54	0.57	0.59	-0.2	0.39	-0.17	0.14	-0.18
Property Plant Equipment	0.82	0.35	0.28	0.28	0.81	0.78	0.35	0.64	0.56	0.76	-0.2	-0.5	-0.5	0.68	0.56		0.74	0.68	-0.4	0.66	0.8	0.0	0.59	-0.4	0.6	-0.29
Good Will	0.65	0.01	0.44	-0.03	0.69	0.69	0.21	0.78	0.52	0.67	-0.27	-0.58	-0.58	0.65	0.62	0.74		0.7	-0.62	0.74	0.75	-0.15	0.64	-0.55	0.52	-0.5
Current Deferred Revenue	0.86	-0.01	0.2	-0.15	0.91	0.87	-0.11	0.75	0.79	0.92	-0.42	-0.81	-0.81	0.87	0.42	0.68	0.7		-0.51	0.66	0.73	-0.24	0.77	-0.75	0.69	-0.67
Net Tangible Assets	-0.47	0.67	-0.54	0.68	-0.6	-0.65	-0.19	-0.72	-0.25	-0.47	0.75	0.85	0.85	-0.68	-0.54	-0.4	-0.62	-0.51		-0.92	-0.82	0.66	-0.39	0.48	-0.06	0.37
Long Term Debt Total	0.63	-0.44	0.51	-0.5	0.76	0.77	0.23	0.75	0.39	0.62	-0.75	-0.86	-0.86	0.78	0.57	0.66	0.74	0.66	-0.92		0.95	-0.59	0.52	-0.54	0.36	-0.38
Capital Surpluse	0.78	-0.23	0.36	-0.31	0.85	0.87	0.16	0.71	0.55	0.76	-0.68	-0.85	-0.85	0.86	0.59	0.8	0.75	0.73	-0.82	0.95		-0.54	0.61	-0.54	0.51	-0.33
Long Term Investments	-0.14	0.7	-0.24	0.78	-0.29	-0.3	0.13	-0.17	-0.12	-0.19	0.88	0.66	0.66	-0.41	-0.2	0.0	-0.15	-0.24	0.66	-0.59	-0.54		-0.18	0.31	-0.04	0.16
Short Long Term Debt	0.79	-0.01	0.19	-0.11	0.81	0.8	0.06	0.43	0.92	0.82	-0.29	-0.61	-0.61	0.75	0.39	0.59	0.64	0.77	-0.39	0.52	0.61	-0.18		-0.4	0.7	-0.55
Cash And Equivalents	-0.44	0.17	-0.36	0.31	-0.58	-0.51	0.15	-0.71	-0.41	-0.57	0.46	0.64	0.64	-0.54	-0.17	-0.4	-0.55	-0.75	0.48	-0.54	-0.54	0.31	-0.4		-0.47	0.79
Net Invested Capital	0.66	0.31	-0.19	0.15	0.64	0.6	-0.28	0.25	0.78	0.72	-0.2	-0.36	-0.36	0.62	0.14	0.6	0.52	0.69	-0.06	0.36	0.51	-0.04	0.7	-0.47		-0.28
Net Working Capital	-0.35	0.16	-0.63	0.28	-0.53	-0.4	-0.2	-0.64	-0.42	-0.45	0.27	0.52	0.52	-0.35	-0.18	-0.29	-0.5	-0.67	0.37	-0.38	-0.33	0.16	-0.55	0.79	-0.28

Click cells to compare fundamentals

Year-To-Date typically refers to a period starting from the beginning of the current year and continuing up to the present day. Investors should becareful when comparing YTD ratios if not much of the year has occurred as research shows that YTD measures are more sensitive to early periods than late.

Competition

Predict Eli Lilly

Eli Return On Tangible Assets

Return On Tangible Assets

0.1

At this time, Eli Lilly's Return On Tangible Assets are fairly stable compared to the past year.

Based on the company's disclosures, Eli Lilly and has a Year To Date Return of 0.0%. This indicator is about the same for the Pharmaceuticals average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).

Eli Year To Date Return Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Eli Lilly's direct or indirect competition against its Year To Date Return to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Eli Lilly could also be used in its relative valuation, which is a method of valuing Eli Lilly by comparing valuation metrics of similar companies.

Eli Lilly is currently under evaluation in year to date return category among its peers.

Eli Lilly ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Eli Lilly's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Eli Lilly's managers, analysts, and investors.

Environmental

Governance

Social

Eli Fundamentals

	Return On Equity	0.84
	Return On Asset	0.15
	Profit Margin	0.24 %
	Operating Margin	0.43 %
	Current Valuation	768.39 B
	Shares Outstanding	898.17 M
	Shares Owned By Insiders	0.16 %
	Shares Owned By Institutions	83.53 %
	Number Of Shares Shorted	7.24 M
	Price To Earning	54.92 X
	Price To Book	52.01 X
	Price To Sales	15.99 X
	Revenue	45.04 B
	Gross Profit	36.62 B
	EBITDA	15.23 B
	Net Income	10.59 B
	Cash And Equivalents	2.07 B
	Cash Per Share	2.97 X
	Total Debt	33.64 B
	Debt To Equity	1.58 %
	Current Ratio	1.13 X
	Book Value Per Share	15.81 X
	Cash Flow From Operations	8.82 B
	Short Ratio	2.11 X
	Earnings Per Share	11.67 X
	Price To Earnings To Growth	1.21 X
	Target Price	1006.63
	Number Of Employees	47 K
	Beta	0.34
	Market Capitalization	720.02 B
	Total Asset	78.71 B
	Retained Earnings	13.54 B
	Working Capital	4.36 B
	Current Asset	12.57 B
	Current Liabilities	8.23 B
	Annual Yield	0.01 %
	Five Year Return	1.83 %
	Net Asset	78.71 B
	Last Dividend Paid	5.2

About Eli Lilly Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Eli Lilly and's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eli Lilly using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eli Lilly and based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
CRM	Salesforce
CRM	Salesforce

Additional Tools for Eli Stock Analysis

When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC